Vir Biotechnology
499 Illinois Suite 500
San Francisco
California
94158
United States
Website: http://www.vir.bio/
Email: info@vir.com
174 articles about Vir Biotechnology
-
Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection
12/9/2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating novel therapeutic combinations for the treatment of chronic hepatitis B virus (HBV) infection.
-
MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID‑19
12/7/2021
Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection.
-
Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.
-
Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant
12/7/2021
Vir Biotechnology, Inc. announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new data that demonstrates sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant.
-
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
12/7/2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced an update to preclinical data on bioRxiv1, a preprint server, demonstrating that sotrovimab, an investigational monoclonal antibody, retains in vitro activity against the full known Omicron spike protein, the new SARS-CoV-2 variant.
-
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
12/2/2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations of the new Omicron SARS-CoV-2 variant, including those found in the binding site of sotrovimab.
-
Early tests of Regeneron’s antibody cocktail show it isn’t as effective against Omicron while a separate tests of Eli Lilly’s antibody cocktail also demonstrated the same.
-
Monoclonal antibodies have proven to be an important therapeutic option in the ongoing battle against COVID-19.
-
While COVID-19 appears to be surging again in the U.S. and Europe, the government is spending billions to acquire antibody and antiviral therapies and edging toward vaccination boosters.
-
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
11/17/2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced US government contracts totaling approximately $1 billion (USD) to purchase sotrovimab.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
11/4/2021
Vir Biotechnology, Inc. provided a corporate update and reported financial results for the third quarter ended September 30, 2021.
-
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
10/21/2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021.
-
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
10/15/2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®.
-
Although there are many effective and safe COVID-19 vaccines around the world, the preferred vaccine is the Pfizer-BioNTech vaccine. For that and more stories, read on.
-
Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
10/6/2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference on Wednesday, Oct. 13, at 9:30 a.m. PT / 12:30 p.m. ET.
-
Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference
9/30/2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference on Wednesday, Oct. 6, at 11:30 a.m. PT / 2:30 p.m. ET.
-
Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
9/8/2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, Sept. 14 at 9:30 a.m. PT / 12:30 p.m. ET.
-
Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
Vir Biotechnology, Inc. announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, Sept. 13, at 4:00 a.m. PT / 7:00 a.m. ET.
-
Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia– First monoclonal antibody authorized in Australia –
8/23/2021
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product, sotrovimab, developed in partnership with GlaxoSmithKline (GSK).